Filing beckons as Lynparza hits the mark in adjuvant breast cancerAstraZeneca’s PARP inhibitor Lynparza has shown a clinical benefit when given as an adjuvant for early breast cancer, Share XFiling beckons as Lynparza hits the mark in adjuvant breast cancerhttps://pharmaphorum.com/news/filing-beckons-as-lynparza-hits-the-mark-in-adjuvant-breast-cancer/
Triple Negative Breast Cancer Drug Development Digital SummitFast-track the Discovery & Development of TNBC Share XTriple Negative Breast Cancer Drug Development Digital Summithttps://pharmaphorum.com/events/triple-negative-breast-cancer-drug-development-digital-summit/
AZ, Merck add pancreatic cancer to Lynparza’s growing use listAstraZeneca and Merck & Co have cemented their lead in the PARP inhibitor class with FDA approval for Share XAZ, Merck add pancreatic cancer to Lynparza’s growing use listhttps://pharmaphorum.com/news/az-merck-add-pancreatic-cancer-to-lynparzas-growing-use-list/
AZ’s Lynparza inches towards ‘game changer’ okay in pancreatic cancerAstraZeneca and Merck & Co are closer to a new use for their PARP inhibitor Lynparza in pancreatic Share XAZ’s Lynparza inches towards ‘game changer’ okay in pancreatic cancerhttps://pharmaphorum.com/news/azs-lynparza-inches-towards-game-changer-okay-in-pancreatic-cancer/
NICE backs Lynparza across the board for BRCA+ovarian cancerAstraZeneca and MSD’s Lynparza has become the first PARP inhibitor to be recommended for all lines of maintenance Share XNICE backs Lynparza across the board for BRCA+ovarian cancerhttps://pharmaphorum.com/news/nice-backs-lynparza-across-the-board-for-brca-ovarian-cancer/
New price gets Clovis’ PARP inhibitor on the CDFNICE has reversed its decision on Clovis Oncology’s PARP inhibitor Rubraca (rucaparib) and will allow the drug to Share XNew price gets Clovis’ PARP inhibitor on the CDFhttps://pharmaphorum.com/news/new-price-gets-clovis-parp-inhibitor-on-the-cdf/
As ESMO opens its doors, GSK and AZ prep ‘all-comer’ ovarian cancer dataGlaxoSmithKline and AstraZeneca will go head-to-head with new data on their PARP inhibitor drugs this weekend, as the Share XAs ESMO opens its doors, GSK and AZ prep ‘all-comer’ ovarian cancer datahttps://pharmaphorum.com/news/as-esmo-opens-its-doors-gsk-and-az-prep-all-comer-ovarian-cancer-data/
Relief for GSK as Tesaro’s Zejula hits the mark in ovarian cancerGlaxoSmithKline raised eyebrows last year when it paid $5.1 billion for Tesaro and its PARP inhibitor Zejula, amid Share XRelief for GSK as Tesaro’s Zejula hits the mark in ovarian cancerhttps://pharmaphorum.com/news/relief-for-gsk-as-tesaros-zejula-hits-the-mark-in-ovarian-cancer/
Strong results for AZ’s Lynparza will help in PARP battleAstraZeneca has announced that its PARP inhibitor cancer treatment Lynparza has recorded strong results in a new phase Share XStrong results for AZ’s Lynparza will help in PARP battlehttps://pharmaphorum.com/news/lynparza-parp-battle/